Aristides Capital LLC Invests $134,000 in Applied Therapeutics, Inc. (NASDAQ:APLT)

Aristides Capital LLC acquired a new stake in Applied Therapeutics, Inc. (NASDAQ:APLT) in the 4th quarter, Holdings Channel reports. The firm acquired 156,507 shares of the company’s stock, valued at approximately $134,000.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Private Advisor Group LLC acquired a new stake in Applied Therapeutics in the fourth quarter valued at $35,000. SG Americas Securities LLC grew its stake in Applied Therapeutics by 169.0% in the 4th quarter. SG Americas Securities LLC now owns 40,747 shares of the company’s stock valued at $35,000 after acquiring an additional 25,601 shares during the last quarter. Intech Investment Management LLC grew its stake in Applied Therapeutics by 176.1% in the 4th quarter. Intech Investment Management LLC now owns 52,631 shares of the company’s stock valued at $45,000 after acquiring an additional 33,567 shares during the last quarter. Swiss National Bank purchased a new position in Applied Therapeutics during the 4th quarter valued at about $126,000. Finally, Y Intercept Hong Kong Ltd acquired a new position in Applied Therapeutics during the third quarter worth about $149,000. 98.31% of the stock is owned by institutional investors and hedge funds.

Applied Therapeutics Stock Performance

Shares of APLT opened at $0.41 on Tuesday. The company has a market capitalization of $47.71 million, a price-to-earnings ratio of -0.25 and a beta of 1.88. Applied Therapeutics, Inc. has a 1 year low of $0.36 and a 1 year high of $10.62. The company’s 50 day simple moving average is $0.54 and its 200 day simple moving average is $3.58.

Analysts Set New Price Targets

Several analysts have recently commented on the stock. William Blair lowered shares of Applied Therapeutics from an “outperform” rating to a “market perform” rating in a research report on Monday, December 23rd. Royal Bank of Canada lowered their target price on Applied Therapeutics from $4.00 to $1.50 and set a “sector perform” rating on the stock in a report on Friday, December 20th. Three analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $6.10.

Applied Therapeutics Profile

Applied Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG.